Pfizer Shows Accelerating Pipeline With Significant Growth In Late-Stage Clinical Development

Pfizer Inc today provided the latest update to its development pipeline, showing significant progress in achieving the company’s growth, productivity and performance goals. The pipeline now includes 114 programs, from Phase 1 through Registration. The number in late-stage (Phase 3) development has grown from 16 to 25 over the past six months. In total, 31 programs advanced to the next stage of development; 13 were discontinued; and one was withdrawn from registration.

More: continued here

Filed under: Pharma Industry on October 3rd, 2008